236 related articles for article (PubMed ID: 22391444)
1. The role of FDG-PET/CT in gynaecological cancers.
Rockall AG; Cross S; Flanagan S; Moore E; Avril N
Cancer Imaging; 2012 Mar; 12(1):49-65. PubMed ID: 22391444
[TBL] [Abstract][Full Text] [Related]
2. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
3. Impact of 18F-FDG PET/CT on target volume delineation in recurrent or residual gynaecologic carcinoma.
Vees H; Casanova N; Zilli T; Imperiano H; Ratib O; Popowski Y; Wang H; Zaidi H; Miralbell R
Radiat Oncol; 2012 Oct; 7():176. PubMed ID: 23088346
[TBL] [Abstract][Full Text] [Related]
4. FDG PET-CT of gynecologic cancers: pearls and pitfalls.
Prabhakar HB; Kraeft JJ; Schorge JO; Scott JA; Lee SI
Abdom Imaging; 2015 Oct; 40(7):2472-85. PubMed ID: 25680500
[TBL] [Abstract][Full Text] [Related]
5. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
7. The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers.
Tsai CC; Tsai CS; Ng KK; Lai CH; Hsueh S; Kao PF; Chang TC; Hong JH; Yen TC
Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1674-83. PubMed ID: 12937950
[TBL] [Abstract][Full Text] [Related]
8. Imaging spectrum and pitfalls of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with tuberculosis.
Ito K; Morooka M; Minamimoto R; Miyata Y; Okasaki M; Kubota K
Jpn J Radiol; 2013 Aug; 31(8):511-20. PubMed ID: 23719763
[TBL] [Abstract][Full Text] [Related]
9. PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison.
Queiroz MA; Kubik-Huch RA; Hauser N; Freiwald-Chilla B; von Schulthess G; Froehlich JM; Veit-Haibach P
Eur Radiol; 2015 Aug; 25(8):2222-30. PubMed ID: 26017734
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Use of 18F-FDG PET CT for External Beam Radiotherapy Planning in Gynaecological Malignancies.
Kerr A; Reed N; Harrand R; Graham K; Sadozye AH
Curr Oncol Rep; 2018 Sep; 20(10):84. PubMed ID: 30206712
[TBL] [Abstract][Full Text] [Related]
11. Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.
Povoski SP; Hall NC; Murrey DA; Chow AZ; Gaglani JR; Bahnson EE; Mojzisik CM; Kuhrt MP; Hitchcock CL; Knopp MV; Martin EW
World J Surg Oncol; 2011 Nov; 9():152. PubMed ID: 22112047
[TBL] [Abstract][Full Text] [Related]
12. Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.
Kitajima K; Ebina Y; Sugimura K
Jpn J Radiol; 2014 Jun; 32(6):313-23. PubMed ID: 24744135
[TBL] [Abstract][Full Text] [Related]
13. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
14. PET/MRI in Gynecologic Malignancy.
Larson M; Lovrec P; Sadowski EA; Pirasteh A
Radiol Clin North Am; 2023 Jul; 61(4):713-723. PubMed ID: 37169433
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
[TBL] [Abstract][Full Text] [Related]
16. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
17. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
Basu S; Saboury B; Torigian DA; Alavi A
Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
20. Characterization of F-18 Fluorodeoxyglucose PET/CT in Granulomatosis with Polyangiitis.
Nelson DR; Johnson GB; Cartin-Ceba R; Specks U
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):342-52. PubMed ID: 26847102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
